Serum Neuropeptide Y Levels Are Associated with TNF-α Levels and Disease Activity in Rheumatoid Arthritis
Background. Neuropeptide Y (NPY) is a sympathetic neurotransmitter with effects on the regulation of inflammatory cells. The role of NPY on autoimmune inflammatory diseases such as rheumatoid arthritis (RA) is not completely understood. Therefore, we evaluate if NPY levels are markers of disease act...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2020/8982163 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566266201636864 |
|---|---|
| author | Melissa Ramirez-Villafaña Ana M. Saldaña-Cruz Javier A. Aceves-Aceves Edsaul E. Perez-Guerrero Nicté S. Fajardo-Robledo Edy D. Rubio-Arellano Cesar A. Nava-Valdivia Maria O. Carrillo-Escalante Sylvia E. Totsuka-Sutto David Cardona-Müller Betsabe Contreras-Haro Mario Salazar-Paramo Ernesto G. Cardona-Muñoz M. Huerta Jorge I. Gamez-Nava Norma A. Rodriguez-Jimenez Laura Gonzalez-Lopez |
| author_facet | Melissa Ramirez-Villafaña Ana M. Saldaña-Cruz Javier A. Aceves-Aceves Edsaul E. Perez-Guerrero Nicté S. Fajardo-Robledo Edy D. Rubio-Arellano Cesar A. Nava-Valdivia Maria O. Carrillo-Escalante Sylvia E. Totsuka-Sutto David Cardona-Müller Betsabe Contreras-Haro Mario Salazar-Paramo Ernesto G. Cardona-Muñoz M. Huerta Jorge I. Gamez-Nava Norma A. Rodriguez-Jimenez Laura Gonzalez-Lopez |
| author_sort | Melissa Ramirez-Villafaña |
| collection | DOAJ |
| description | Background. Neuropeptide Y (NPY) is a sympathetic neurotransmitter with effects on the regulation of inflammatory cells. The role of NPY on autoimmune inflammatory diseases such as rheumatoid arthritis (RA) is not completely understood. Therefore, we evaluate if NPY levels are markers of disease activity in RA and if there is a correlation between NPY levels and tumor necrosis factor-alpha (TNF-α), leptin, and interleukin 6 (IL-6) levels. Methods. Cross-sectional design, including 108 women with RA. We assessed disease activity by DAS28-ESR (considering active disease a score of ≥2.6). Serum NPY levels and anti-CCP2 antibody, TNF-α, IL-6, and leptin levels were quantified (ELISA). Results. Sixty-eight RA had an active disease (RA-active), and 40 were in remission (RA-remission). RA-active patients had higher NPY levels vs. RA-remission (22.8±13.6 vs. 17.8±10.3; p=0.04). NPY levels correlated with increased TNF-α levels (r=0.32, p=0.001). Leptin or IL-6 did not correlate with NPY levels. In the logistic regression analysis, NPY increased the risk of disease activity (OR: 1.04, 95% CI 1.006-1.09, and p=0.03). Conclusion. Higher NPY levels are an independent marker of disease activity in RA. This study encourages the quantification of NPY levels as a surrogate marker for RA-active. Future studies evaluating the role of NPY levels interacting with other proinflammatory cytokines are required. |
| format | Article |
| id | doaj-art-2ed3a03221eb4ff781cc6938608d9796 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-2ed3a03221eb4ff781cc6938608d97962025-02-03T01:04:38ZengWileyJournal of Immunology Research2314-88612314-71562020-01-01202010.1155/2020/89821638982163Serum Neuropeptide Y Levels Are Associated with TNF-α Levels and Disease Activity in Rheumatoid ArthritisMelissa Ramirez-Villafaña0Ana M. Saldaña-Cruz1Javier A. Aceves-Aceves2Edsaul E. Perez-Guerrero3Nicté S. Fajardo-Robledo4Edy D. Rubio-Arellano5Cesar A. Nava-Valdivia6Maria O. Carrillo-Escalante7Sylvia E. Totsuka-Sutto8David Cardona-Müller9Betsabe Contreras-Haro10Mario Salazar-Paramo11Ernesto G. Cardona-Muñoz12M. Huerta13Jorge I. Gamez-Nava14Norma A. Rodriguez-Jimenez15Laura Gonzalez-Lopez16Programa de Doctorado en Ciencias Médicas, Universidad de Colima, 28040 Colima, Colima, MexicoInstituto de Terapeutica Experimental y Clínica, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), 44340 Guadalajara, Jalisco, MexicoPrograma de Doctorado en Farmacología, CUCS, Universidad de Guadalajara, 44340 Guadalajara, Jalisco, MexicoInstituto de Investigación en Ciencias Biomédicas, CUCS, UdeG, 44340 Guadalajara, Jalisco, MexicoLaboratorio de Investigación y Desarrollo Farmacéutico, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, 44430 Guadalajara, Jalisco, MexicoInstituto de Terapeutica Experimental y Clínica, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), 44340 Guadalajara, Jalisco, MexicoDepartamento de Microbiología y Patología, CUCS, Universidad de Guadalajara, 44340 Guadalajara, Jalisco, MexicoUnidad de Investigación Biomédica 02, Hospital de Especialidades, Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS), 44340 Guadalajara, Jalisco, MexicoDepartamento de Fisiología, CUCS, Universidad de Guadalajara, 44340 Guadalajara, Jalisco, MexicoDepartamento de Fisiología, CUCS, Universidad de Guadalajara, 44340 Guadalajara, Jalisco, MexicoDepartamento de Ciencias Biomédicas, Centro Universitario de Tonalá, Universidad de Guadalajara, 45425 Tonalá, Jalisco, MexicoUnidad de Investigación Biomédica 02, Hospital de Especialidades, Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS), 44340 Guadalajara, Jalisco, MexicoDepartamento de Fisiología, CUCS, Universidad de Guadalajara, 44340 Guadalajara, Jalisco, MexicoCentro Universitario de Investigaciones Biomédicas, Universidad de Colima, 28040 Colima, Colima, MexicoUnidad de Investigación Biomédica 02, Hospital de Especialidades, Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS), 44340 Guadalajara, Jalisco, MexicoInstituto de Terapeutica Experimental y Clínica, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara (UdeG), 44340 Guadalajara, Jalisco, MexicoPrograma de Doctorado en Farmacología, CUCS, Universidad de Guadalajara, 44340 Guadalajara, Jalisco, MexicoBackground. Neuropeptide Y (NPY) is a sympathetic neurotransmitter with effects on the regulation of inflammatory cells. The role of NPY on autoimmune inflammatory diseases such as rheumatoid arthritis (RA) is not completely understood. Therefore, we evaluate if NPY levels are markers of disease activity in RA and if there is a correlation between NPY levels and tumor necrosis factor-alpha (TNF-α), leptin, and interleukin 6 (IL-6) levels. Methods. Cross-sectional design, including 108 women with RA. We assessed disease activity by DAS28-ESR (considering active disease a score of ≥2.6). Serum NPY levels and anti-CCP2 antibody, TNF-α, IL-6, and leptin levels were quantified (ELISA). Results. Sixty-eight RA had an active disease (RA-active), and 40 were in remission (RA-remission). RA-active patients had higher NPY levels vs. RA-remission (22.8±13.6 vs. 17.8±10.3; p=0.04). NPY levels correlated with increased TNF-α levels (r=0.32, p=0.001). Leptin or IL-6 did not correlate with NPY levels. In the logistic regression analysis, NPY increased the risk of disease activity (OR: 1.04, 95% CI 1.006-1.09, and p=0.03). Conclusion. Higher NPY levels are an independent marker of disease activity in RA. This study encourages the quantification of NPY levels as a surrogate marker for RA-active. Future studies evaluating the role of NPY levels interacting with other proinflammatory cytokines are required.http://dx.doi.org/10.1155/2020/8982163 |
| spellingShingle | Melissa Ramirez-Villafaña Ana M. Saldaña-Cruz Javier A. Aceves-Aceves Edsaul E. Perez-Guerrero Nicté S. Fajardo-Robledo Edy D. Rubio-Arellano Cesar A. Nava-Valdivia Maria O. Carrillo-Escalante Sylvia E. Totsuka-Sutto David Cardona-Müller Betsabe Contreras-Haro Mario Salazar-Paramo Ernesto G. Cardona-Muñoz M. Huerta Jorge I. Gamez-Nava Norma A. Rodriguez-Jimenez Laura Gonzalez-Lopez Serum Neuropeptide Y Levels Are Associated with TNF-α Levels and Disease Activity in Rheumatoid Arthritis Journal of Immunology Research |
| title | Serum Neuropeptide Y Levels Are Associated with TNF-α Levels and Disease Activity in Rheumatoid Arthritis |
| title_full | Serum Neuropeptide Y Levels Are Associated with TNF-α Levels and Disease Activity in Rheumatoid Arthritis |
| title_fullStr | Serum Neuropeptide Y Levels Are Associated with TNF-α Levels and Disease Activity in Rheumatoid Arthritis |
| title_full_unstemmed | Serum Neuropeptide Y Levels Are Associated with TNF-α Levels and Disease Activity in Rheumatoid Arthritis |
| title_short | Serum Neuropeptide Y Levels Are Associated with TNF-α Levels and Disease Activity in Rheumatoid Arthritis |
| title_sort | serum neuropeptide y levels are associated with tnf α levels and disease activity in rheumatoid arthritis |
| url | http://dx.doi.org/10.1155/2020/8982163 |
| work_keys_str_mv | AT melissaramirezvillafana serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis AT anamsaldanacruz serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis AT javieraacevesaceves serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis AT edsauleperezguerrero serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis AT nictesfajardorobledo serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis AT edydrubioarellano serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis AT cesaranavavaldivia serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis AT mariaocarrilloescalante serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis AT sylviaetotsukasutto serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis AT davidcardonamuller serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis AT betsabecontrerasharo serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis AT mariosalazarparamo serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis AT ernestogcardonamunoz serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis AT mhuerta serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis AT jorgeigameznava serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis AT normaarodriguezjimenez serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis AT lauragonzalezlopez serumneuropeptideylevelsareassociatedwithtnfalevelsanddiseaseactivityinrheumatoidarthritis |